- Home
- SPFI vs LENZ Comparison
SPFI vs LENZ Comparison
Compare SPFI & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | LENZ |
|---|---|---|
| Founded | 1941 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 632.4M | 609.5M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPFI | LENZ |
|---|---|---|
| Price | $41.58 | $11.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $42.25 | ★ $56.25 |
| AVG Volume (30 Days) | 56.1K | ★ 855.9K |
| Earning Date | 04-27-2026 | 04-16-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.55 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.65 | N/A |
| Revenue Next Year | $9.40 | $157.21 |
| P/E Ratio | $16.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.01 | $11.50 |
| 52 Week High | $44.00 | $50.19 |
Technical Indicators
Market Signals| Indicator | SPFI | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 48.35 | 27.63 |
| Support Level | $41.33 | N/A |
| Resistance Level | $41.91 | $30.24 |
| Average True Range (ATR) | 1.12 | 0.94 |
| MACD | -0.18 | -0.16 |
| Stochastic Oscillator | 9.36 | 7.75 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.